Christine M. Pallares
Christine Pallares counsels clients through complex transactions, with a focus on mergers and acquisitions and capital-raising activities. With more than 25 years of transactional experience across many practice areas, Christine uses her broad background and depth of knowledge to assist clients in structuring, negotiating, and executing complex corporate transactions. She represents companies in a number of industries, particularly healthcare and life sciences, real estate, and energy and renewables.
Christine is experienced with a broad range of complex M&A transactions, including public and private acquisitions, cross-border transactions, private equity investments, joint ventures and other strategic alliances, and spin-offs. She represents both start-ups and public companies in all types of capital-raising transactions, including private placements, initial public offerings, registered debt and equity offerings, high-yield debt offerings, Rule 144A and Regulation S offerings, and bank financings.
Christine also regularly advises public companies and their boards on corporate governance matters, U.S. Securities and Exchange Commission compliance and reporting, and stock exchange listing standards.
Prior to joining Hogan Lovells, Christine was a partner in a major New York-based firm, where she practiced for more than 12 years, including two years in their Hong Kong office.
Represented a university in the transfer of its medical school to a new joint venture between the university and a hospital system.
Represented an academic medical center in the acquisition of several hospitals.
Represented a Japanese real estate company in the acquisition of a U.S. real estate investment company.
Represented a German healthcare company in the acquisition of a U.S. medical laboratory.
Represented the sponsor in a US$744m Rule 144A offering to finance the construction of a 250 MW solar project.
Represented a handbag and accessories company in its US$325m sale to a Hong Kong- listed company.
Represented a home healthcare company in its US$112m sale to a private equity firm.
Represented the initial purchasers in a US$330m Rule 144A common stock offering for a managed healthcare services company.